Tuesday, October 15, 2024
9:51 AM EST – BriaCell Therapeutics Corp. : Provided a clinical engagement update of its pivotal Phase 3 study of Bria-IMT™ in combination with immune check point inhibitor in metastatic breast cancer (MBC). The study will enroll up to 354 patients randomized 1:1 to the BriaCell combination regimen or physician’s choice and will include a small number (n=50) of patients randomized to Bria-IMT™ monotherapy. BriaCell Therapeutics Corp. (T.BCT) shares were down $0.06 at 1.28.
Stocks in Play: BriaCell Therapeutics Corp., Tue, 15 Oct 2024 09:57:06 EST